BC-819 has completed phase 1/2a trials in pancreatic, ovarian and bladder cancers, with current clinical development focused on bladder cancer, where H19 is often suppressed in normal cells but upregulated in tumor cells (176). This evidence concerns the gene H19 and urinary bladder cancer.